SCHEMBL6539256

SCHEMBL6539256

O=[C]c1c(C(=O)O)ccc2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WDR5 P61964 1/20 0.61
LDHA P00338 1/20 0.59
NR4A1 P22736 1/20 0.55
NR4A2 P43354 1/20 0.55
NR4A3 Q92570 1/20 0.55
CDC25B P30305 1/20 0.49
ALDH1A1 P00352 6/20 0.45
HPGD P15428 5/20 0.45
LMNA P02545 1/20 0.45
CSNK2A2 P19784 1/20 0.45
CSNK2B P67870 1/20 0.45
CSNK2A1 P68400 1/20 0.45
KDM4E B2RXH2 3/20 0.44
GLA P06280 2/20 0.44
GAA P10253 1/20 0.44
CFTR P13569 1/20 0.43
SOS1 Q07889 1/20 0.43
PTPN1 P18031 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3282521 0.84 WDR5 (0.47) WDR5LDHANR4A1NR4A2NR4A3
SCHEMBL7191625 0.84 WDR5 (0.59) WDR5LDHANR4A1NR4A2NR4A3
SCHEMBL3246521 0.84 ALDH1A1 (0.46) WDR5LDHANR4A1NR4A2NR4A3
SCHEMBL63859 0.81 CDC25B (0.57) WDR5NR4A1NR4A2NR4A3CDC25B
SCHEMBL6948196 0.80 WDR5 (0.42) WDR5LDHANR4A1NR4A2NR4A3
SCHEMBL6539923 0.80 MAPT (0.49) WDR5NR4A2ALDH1A1HPGDLMNA
SCHEMBL4938311 0.78 CYP1A1 (0.46) WDR5LDHAALDH1A1HPGDLMNA
SCHEMBL5911605 0.78 MEN1 (0.49) WDR5LDHANR4A1NR4A2NR4A3
SCHEMBL10898764 0.77 PTPN1 (0.56) WDR5ALDH1A1HPGDKDM4EGAA
SCHEMBL29721418 0.76 WDR5 (1.00) WDR5LDHANR4A1NR4A2NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed
WO-2000011017-A9 CARDENOLIDE COMPLEXES USEFUL AS CARDIOACTIVE AGENTS UNIV COLUMBIA (US) 2000-06-22 WO disclosed
WO-2000011017-A2 CARDENOLIDE COMPLEXES USEFUL AS CARDIOACTIVE AGENTS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2000-03-02 WO disclosed
US-3936478-A Process for the preparation of desmosterol derivatives TEIJIN LIMITED (JA) 1976-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB WDR5 4659/4885LDHA 333/4885NR4A1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.